50% Hemolysis Inhibition Test: Principles, Methods, and Applications

The 50% hemolysis inhibition test (also referred to as the CH50 inhibition assay or median hemolytic inhibition assay) is a quantitative immunological method used to measure complement-mediated hemolytic activity and the capacity of test articles to inhibit it by 50%. This assay is widely applied in immunotoxicology screening of blood-contacting medical devices per ISO 10993-4, complement-targeted drug development, vaccine quality control, and clinical evaluation of complement function. This article explains the technical principle, sample requirements, test items, procedural workflow, and practical applications of the 50% hemolysis inhibition test.

Technical Overview

The 50% hemolysis inhibition test is a classical complement-dependent immunoassay based on the lytic action of complement on antibody-sensitized erythrocytes. In the standard system, sheep red blood cells (SRBC) coated with rabbit anti-sheep hemolysin (amboceptor) form antigen-antibody complexes that activate the classical complement pathway. Upon activation, the terminal complement components assemble into membrane attack complexes, resulting in erythrocyte lysis and release of hemoglobin into the supernatant.

The extent of hemolysis is quantified spectrophotometrically by measuring hemoglobin release at approximately 540-541 nm. Because the relationship between complement concentration and the percentage of hemolysis is sigmoidal rather than linear, the 50% lysis point is used as the most precise and reproducible endpoint. In the inhibition format, a test article is introduced into the hemolytic system, and its capacity to suppress complement-mediated lysis is determined. The concentration or dilution of the test article that reduces hemolysis to 50% of the uninhibited control value is reported as the inhibition endpoint (IC50 or IH50).

Key quantitative outputs of the assay include:

• Total classical pathway complement activity (CH50), expressed in units per milliliter (U/mL)
• Alternative pathway hemolytic activity (AH50)
• Inhibitory potency of test articles (IC50/IH50 values)
• Anti-complement activity of biological products or biomaterials
• Hemolytic antibody (hemolysin) titers in antisera or vaccines

Testing Samples

Clinical and Biological Samples

Human and animal serum samples are the most common specimens. Because complement proteins are thermally labile, blood should be allowed to clot at refrigerated temperature, separated within one to two hours of collection, and tested promptly or stored frozen at -70 °C or below. Repeated freeze-thaw cycles and heat inactivation must be avoided, as both destroy complement activity.

Pharmaceuticals and Biological Products

Monoclonal antibodies, complement-inhibiting therapeutics, plasma-derived products, and vaccines may be evaluated for anti-complement activity or hemolysis-inhibiting potency. These tests support lot release, comparability studies, and immunotoxicity assessment during product development.

Medical Device and Biomaterial Extracts

Extracts of blood-contacting devices and materials are prepared according to ISO 10993-12 and evaluated for their effect on complement hemolytic activity as part of hemocompatibility testing under ISO 10993-4. Test articles may include catheters, oxygenators, dialysis membranes, stents, and surface coatings.

Nanomedicines and Drug Delivery Systems

Liposomes, lipid nanoparticles, micelles, and polymeric carriers are known potential activators or inhibitors of complement. The 50% hemolysis inhibition test provides a screening tool for assessing complement interactions relevant to infusion reactions and complement activation-related pseudoallergy (CARPA).

Testing Items

Typical test items offered within the scope of the 50% hemolysis inhibition test include:

• Total complement activity (CH50) in human or animal serum
• Alternative pathway complement activity (AH50) using unsensitized rabbit erythrocytes
• Complement inhibition potency (IC50/IH50) of small molecules, peptides, and antibodies
• Anti-complement activity screening for biologics and device extracts
• Complement activation marker measurement (C3a, C5a, Bb, SC5b-9) by immunoassay as confirmatory endpoints
• Hemolytic antibody titration for vaccine and antiserum characterization

Testing Methods

Reagent Preparation

Sheep erythrocytes are washed and standardized to a defined cell concentration, then sensitized with an optimized dilution of rabbit anti-sheep hemolysin to produce antibody-coated cells (EA cells). A source of complement, typically fresh or preserved guinea pig serum for classical pathway assays or normal human serum, is standardized and maintained under cold-chain conditions. All buffers, including veronal-buffered saline with calcium and magnesium, are prepared and pH-verified prior to use.

Assay Procedure

The core procedure involves the following steps: serial dilutions of complement source or test article are prepared in microplates or tubes; standardized EA cells are added to each dilution; mixtures are incubated at 37 °C for a defined period, typically 30 to 60 minutes, to allow complement-mediated lysis; cells are then centrifuged, and hemoglobin release in the supernatant is measured at 540-541 nm. In the inhibition format, graded concentrations of the test article are pre-incubated with a fixed amount of complement before the addition of EA cells.

Controls and Reference Standards

Each run includes a 100% hemolysis control (cells lysed with water or ammonium chloride solution), a 0% hemolysis blank (cells without complement), uninhibited hemolysis controls, and a reference serum of known CH50 activity. Replicate wells are performed to verify precision.

Data Analysis

Raw absorbance values are converted to percent hemolysis, and the classical CH50 is calculated using the von Krogh transformation, in which the logit of hemolysis is plotted against the logarithm of complement concentration. For inhibition studies, percent inhibition is calculated relative to the uninhibited control, and IC50 values are derived by four-parameter logistic curve fitting. Results are reported with dilution factors, units per milliliter, and confidence intervals where applicable.

Quality Acceptance Criteria

The assay is considered valid when the blank control shows negligible hemolysis, the 100% lysis control falls within established absorbance ranges, the reference serum result is within its assigned tolerance interval, and replicate coefficients of variation do not exceed predefined limits, commonly 10-15%.

Applications

The 50% hemolysis inhibition test serves multiple purposes across research, clinical, and regulatory contexts:

• Hemocompatibility and immunotoxicology evaluation of blood-contacting medical devices in accordance with ISO 10993-4 and ISO 10993-12
• Complement activation assessment of solid materials using recognized procedures such as ASTM F1984 and ASTM F2065 for classical and alternative pathway screening
• Potency and anti-complement activity testing of biological products, antisera, and vaccines in support of lot release specifications
• Preclinical and clinical development of complement-inhibiting therapeutics, including dose-response characterization
• Safety assessment of nanomedicines and infusion products associated with complement activation-related pseudoallergy
• Clinical laboratory investigation of inherited or acquired complement deficiencies and monitoring of complement consumption in autoimmune disease

Accredited third-party laboratories routinely perform these assays under quality management systems aligned with ISO/IEC 17025, providing data suitable for regulatory submissions and product registration.

FAQ

What does a reduced CH50 value indicate?

A reduced CH50 indicates decreased total classical pathway complement activity, which may result from complement consumption by immune complexes, inherited complement component deficiency, improper sample handling, or inhibition by the test article. Further testing of individual components or activation markers such as C3a and SC5b-9 is recommended to identify the underlying cause.

What is the difference between CH50 and AH50?

CH50 measures the functional activity of the classical pathway using antibody-sensitized sheep erythrocytes, while AH50 evaluates the alternative pathway using unsensitized rabbit erythrocytes in a buffer that blocks classical pathway activation. Running both assays in parallel helps localize complement defects to a specific pathway.

How should samples be collected and shipped?

Serum should be separated promptly, kept cold, and shipped on dry ice with temperature monitoring. Hemolyzed, heat-inactivated, or repeatedly frozen-thawed samples are not suitable, as they yield falsely low activity.

Which standards govern the test?

Relevant reference frameworks include ISO 10993-4 for hemocompatibility testing of medical devices, ISO 10993-12 for sample preparation, ASTM F1984 and ASTM F2065 for complement activation by solid materials, and applicable pharmacopoeial methods for biological product testing.

What is the typical turnaround time?

For routine samples, testing and reporting are generally completed within seven to fifteen working days after sample acceptance, depending on the complexity of the study design and the number of test concentrations required.